Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCDFLQ)

• Drug Name: Pyrazolo[4,3-c]pyridine derivative 2 Drug Info
• Synonyms: PMID27774824-Compound-Figure7compound1
• Cross-matching ID: TTD Drug ID: DMCDFLQ

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 2 (JAK-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[2]
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[3]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[4]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[5]
Fedratinib	DM4ZBK6	Myelofibrosis	2A20.2	Approved	[6]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[7]
XL019	DMJ6F5C	Solid tumour/cancer	2A00-2F9Z	Phase 3	[7]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[8]
CTP-543	DM3SYOK	Alopecia	ED70	Phase 2	[9]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[10]

Drug(s) Targeting Tyrosine-protein kinase Tec (PSCTK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[11]
PMID24915291C31	DMN7QB8	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Janus kinase 3 (JAK-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[12]
Ritlecitinib	DMYKNME	Alopecia areata	ED70.2	Approved	[13]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[14]
VX-509	DM2U3MX	Rheumatoid arthritis	FA20	Phase 2/3	[3]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[13]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[15]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[16]
TD-8236	DMTOMJN	Asthma	CA23	Phase 2	[17]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[18]
SNA-125	DM8L1GJ	Atopic dermatitis	EA80	Phase 1	[13]

Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[19]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[20]
Zanubrutinib	DMJWRQP	Mantle cell lymphoma	2A85.5	Approved	[21]
Pirtobrutinib	DMRG1X3	Non-hodgkin lymphoma	2B33.5	Approved	[22]
GDC-0853	DMBEL3Q	Multiple sclerosis	8A40	Phase 3	[9]
ICP-022	DMU72KL	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[23]
Tolebrutinib	DML19V6	Multiple sclerosis	8A40	Phase 3	[24]
CC-292	DMJR9H0	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[25]
BMS-986142	DMZB8AJ	Rheumatoid arthritis	FA20	Phase 2	[9]
LOU064	DME8O5K	Chronic idiopathic urticaria	EB00.1	Phase 2	[13]

Drug(s) Targeting Janus kinase 1 (JAK-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[3]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[4]
Upadacitinib	DM32B5U	Rheumatoid arthritis	FA20	Approved	[26]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[27]
SHR0302	DMUL8ZT	Ulcerative colitis	DD71	Phase 3	[28]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[13]
CTP-543	DM3SYOK	Alopecia	ED70	Phase 2	[9]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[27]
PF-06700841	DMMGSFV	Asthma	CA23	Phase 2	[13]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[15]

Drug(s) Targeting B lymphocyte kinase (BLK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[11]
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[29]
PMID24915291C31	DMN7QB8	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting TYK2 tyrosine kinase (TYK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deucravacitinib	DMAR1YS	Plaque psoriasis	EA90.0	Approved	[13]
PF-06700841	DMMGSFV	Asthma	CA23	Phase 2	[13]
PF-06826647	DM5H8V1	Plaque psoriasis	EA90.0	Phase 2	[13]
PF-06826647	DM5H8V1	Plaque psoriasis	EA90.0	Phase 2	[30]
NDI-034858	DM2FJE7	Psoriatic arthritis	FA21	Phase 2	[31]
PMID27774824-Compound-Figure9Example2down	DMXAV42	N. A.	N. A.	Patented	[1]
Aminotriazolopyridine derivative 1	DMW2LZ0	N. A.	N. A.	Patented	[1]
Imidazo[4,5-c]pyridine derivative 2	DMFDRJT	N. A.	N. A.	Patented	[1]
PMID27774824-Compound-Figure11Example1up	DMH1W8F	N. A.	N. A.	Patented	[1]
Imidazo[4,5-c]pyridine derivative 1	DM4KBZQ	N. A.	N. A.	Patented	[1]

Drug(s) Targeting T-cell-specific kinase (ITK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JTE-051	DM2LBHN	Plaque psoriasis	EA90.0	Phase 2	[32]
CPI-818	DMMBQ20	T-cell lymphoma	2A90	Phase 1	[33]
PMID27774824-Compound-Figure3Example7	DMXDOGK	N. A.	N. A.	Patented	[1]
BMS-509744	DMGH1LX	Inflammation	1A00-CA43.1	Investigative	[34]
BMS-488516	DM6Y1QF	Inflammation	1A00-CA43.1	Investigative	[34]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B lymphocyte kinase (BLK)	TTNDSC3	BLK_HUMAN	Inhibitor	[1]
Janus kinase 1 (JAK-1)	TT6DM01	JAK1_HUMAN	Inhibitor	[1]
Janus kinase 2 (JAK-2)	TTRMX3V	JAK2_HUMAN	Inhibitor	[1]
Janus kinase 3 (JAK-3)	TTT7PJU	JAK3_HUMAN	Inhibitor	[1]
T-cell-specific kinase (ITK)	TT3C80U	ITK_HUMAN	Inhibitor	[1]
TYK2 tyrosine kinase (TYK2)	TTBYWP2	TYK2_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase Tec (PSCTK4)	TT1ZV49	TEC_HUMAN	Inhibitor	[1]

References

• [1] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [2] Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
• [3] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [4] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [5] National Cancer Institute Drug Dictionary (drug id 609888).
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [7] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [8] Company report (Portola Pharmaceuticals)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
• [11] Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
• [15] Clinical pipeline report, company report or official report of Aclaris Therapeutics.
• [16] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [18] The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
• [20] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [22] Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
• [23] Clinical pipeline report, company report or official report of InnoCare Pharma.
• [24] Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
• [25] Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
• [26] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
• [28] Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
• [29] Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
• [30] Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577.
• [31] Clinical pipeline report, company report or official report of Nimbus Therapeutics
• [32] Characterisation of a K390R ITK Kinase Dead Transgenic Mouse - Implications for ITK as a Therapeutic Target. PLoS One. 2014; 9(9): e107490.
• [33] Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
• [34] Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3.